SCOP Search:   
        by sunid, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: All beta proteins (24004)
(-)
Fold: Acid proteases (1120)
(-)
Superfamily: Acid proteases (1120)
(-)
Family: Retroviral protease (retropepsin) (591)
(-)
Protein domain: Human immunodeficiency virus type 1 protease (514)
(-)
Human immunodeficiency virus type 1 [TaxId: 11676] (424)
1A30A:; B:HIV-1 PROTEASE COMPLEXED WITH A TRIPEPTIDE INHIBITOR
1A8GA:; B:HIV-1 PROTEASE IN COMPLEX WITH SDZ283-910
1A8KA:; B:; D:; E:CRYSTALLOGRAPHIC ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS 1 PROTEASE WITH AN ANALOG OF THE CONSERVED CA-P2 SUBSTRATE: INTERACTIONS WITH FREQUENTLY OCCURRING GLUTAMIC ACID RESIDUE AT P2' POSITION OF SUBSTRATES
1A94A:; B:; D:; E:STRUCTURAL BASIS FOR SPECIFICITY OF RETROVIRAL PROTEASES
1A9MA:; B:G48H MUTANT OF HIV-1 PROTEASE IN COMPLEX WITH A PEPTIDIC INHIBITOR U-89360E
1AAQA:; B:HYDROXYETHYLENE ISOSTERE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE: STRUCTURE-ACTIVITY ANALYSIS USING ENZYME KINETICS, X-RAY CRYSTALLOGRAPHY, AND INFECTED T-CELL ASSAYS
1AIDA:; B:STRUCTURE OF A NON-PEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE: DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN
1AJVA:; B:HIV-1 PROTEASE IN COMPLEX WITH THE CYCLIC SULFAMIDE INHIBITOR AHA006
1AJXA:; B:HIV-1 PROTEASE IN COMPLEX WITH THE CYCLIC UREA INHIBITOR AHA001
1AXAA:; B:ACTIVE-SITE MOBILITY IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AS DEMONSTRATED BY CRYSTAL STRUCTURE OF A28S MUTANT
1B6JA:; B:HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 1
1B6KA:; B:HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 5
1B6LA:; B:HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 4
1B6MA:; B:HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 6
1B6PA:; B:HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 7
1BDLA:; B:HIV-1 (2:31-37) PROTEASE COMPLEXED WITH INHIBITOR SB203386
1BDQA:; B:HIV-1 (2:31-37, 47, 82) PROTEASE COMPLEXED WITH INHIBITOR SB203386
1BDRA:; B:HIV-1 (2: 31, 33-37) PROTEASE COMPLEXED WITH INHIBITOR SB203386
1BV7A:; B:COUNTERACTING HIV-1 PROTEASE DRUG RESISTANCE: STRUCTURAL ANALYSIS OF MUTANT PROTEASES COMPLEXED WITH XV638 AND SD146, CYCLIC UREA AMIDES WITH BROAD SPECIFICITIES
1BV9A:; B:HIV-1 PROTEASE (I84V) COMPLEXED WITH XV638 OF DUPONT PHARMACEUTICALS
1BVEA:; B:HIV-1 PROTEASE-DMP323 COMPLEX IN SOLUTION, NMR, 28 STRUCTURES
1BVGA:; B:HIV-1 PROTEASE-DMP323 COMPLEX IN SOLUTION, NMR MINIMIZED AVERAGE STRUCTURE
1BWAA:; B:HIV-1 PROTEASE (V82F/I84V) DOUBLE MUTANT COMPLEXED WITH XV638 OF DUPONT PHARMACEUTICALS
1BWBA:; B:HIV-1 PROTEASE (V82F/I84V) DOUBLE MUTANT COMPLEXED WITH SD146 OF DUPONT PHARMACEUTICALS
1C6XA:; B:ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP.
1C6YA:; B:ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP.
1C6ZA:; B:ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP.
1C70A:; B:ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP.
1CPIA:; B:REGIOSELECTIVE STRUCTURAL AND FUNCTIONAL MIMICRY OF PEPTIDES. DESIGN OF HYDROLYTICALLY STABLE CYCLIC PEPTIDOMIMETIC INHIBITORS OF HIV-1 PROTEASE
1D4HA:; B:HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA435
1D4IA:; B:HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA425
1D4JA:; B:HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR MSL370
1D4KA:; B:HIV-1 PROTEASE COMPLEXED WITH A MACROCYCLIC PEPTIDOMIMETIC INHIBITOR
1D4LA:; B:HIV-1 PROTEASE COMPLEXED WITH A MACROCYCLIC PEPTIDOMIMETIC INHIBITOR
1D4SA:; B:HIV-1 PROTEASE V82F/I84V DOUBLE MUTANT/TIPRANAVIR COMPLEX
1D4YA:; B:HIV-1 PROTEASE TRIPLE MUTANT/TIPRANAVIR COMPLEX
1DAZC:; D:STRUCTURAL AND KINETIC ANALYSIS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE
1DIFA:; B:HIV-1 PROTEASE IN COMPLEX WITH A DIFLUOROKETONE CONTAINING INHIBITOR A79285
1DMPA:; B:STRUCTURE OF HIV-1 PROTEASE COMPLEX
1DW6C:; D:STRUCTURAL AND KINETIC ANALYSIS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE
1EBKC:; D:; E:; F:STRUCTURAL AND KINETIC ANALYSIS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE
1EBWA:; B:HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA322
1EBYA:; B:HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA369
1EBZA:; B:HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA388
1EC0A:; B:HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA403
1EC1A:; B:HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA409
1EC2A:; B:HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA428
1EC3A:; B:HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR MSA367
1F7AA:; B:HOW DOES A SYMMETRIC DIMER RECOGNIZE AN ASYMMETRIC SUBSTRATE? A SUBSTRATE COMPLEX OF HIV-1 PROTEASE.
1FB7A:CRYSTAL STRUCTURE OF AN IN VIVO HIV-1 PROTEASE MUTANT IN COMPLEX WITH SAQUINAVIR: INSIGHTS INTO THE MECHANISMS OF DRUG RESISTANCE
1FEJC:; D:STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FF0C:; D:STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES.
1FFFC:; D:STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE : HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES.
1FFIC:; D:STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FG6C:; D:STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FG8C:; D:STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FGCC:; D:STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FQXA:; B:CRYSTAL STRUCTURE OF THE COMPLEX OF HIV-1 PROTEASE WITH A PEPTIDOMIMETIC INHIBITOR
1G2KA:; B:HIV-1 PROTEASE WITH CYCLIC SULFAMIDE INHIBITOR, AHA047
1G35A:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH INHIBITOR, AHA024
1G6LA:1-99; A:1001-10991.9A CRYSTAL STRUCTURE OF TETHERED HIV-1 PROTEASE
1GNMA:; B:HIV-1 PROTEASE MUTANT WITH VAL 82 REPLACED BY ASP (V82D) COMPLEXED WITH U89360E (INHIBITOR)
1GNNA:; B:HIV-1 PROTEASE MUTANT WITH VAL 82 REPLACED BY ASN (V82N) COMPLEXED WITH U89360E (INHIBITOR)
1GNOA:; B:HIV-1 PROTEASE (WILD TYPE) COMPLEXED WITH U89360E (INHIBITOR)
1HBVA:; B:A CHECK ON RATIONAL DRUG DESIGN. CRYSTAL STRUCTURE OF A COMPLEX OF HIV-1 PROTEASE WITH A NOVEL GAMMA-TURN MIMETIC
1HEFE:THE CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF HYDROXYETHYLENE-BASED INHIBITORS BOUND TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE SHOW THAT THE INHIBITORS ARE PRESENT IN TWO DISTINCT ORIENTATIONS
1HEGE:THE CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF HYDROXYETHYLENE-BASED INHIBITORS BOUND TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE SHOW THAT THE INHIBITORS ARE PRESENT IN TWO DISTINCT ORIENTATIONS
1HHPA:THE THREE-DIMENSIONAL STRUCTURE OF THE ASPARTYL PROTEASE FROM THE HIV-1 ISOLATE BRU
1HIHA:; B:COMPARATIVE ANALYSIS OF THE X-RAY STRUCTURES OF HIV-1 AND HIV-2 PROTEASES IN COMPLEX WITH CGP 53820, A NOVEL PSEUDOSYMMETRIC INHIBITOR
1HIVA:; B:CRYSTAL STRUCTURE OF A COMPLEX OF HIV-1 PROTEASE WITH A DIHYDROETHYLENE-CONTAINING INHIBITOR: COMPARISONS WITH MOLECULAR MODELING
1HOSA:; B:INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE BY A C2-SYMMETRIC PHOSPHINATE SYNTHESIS AND CRYSTALLOGRAPHIC ANALYSIS
1HPOA:; B:HIV-1 PROTEASE TRIPLE MUTANT/U103265 COMPLEX
1HPSA:; B:RATIONAL DESIGN, SYNTHESIS AND CRYSTALLOGRAPHIC ANALYSIS OF A HYDROXYETHYLENE-BASED HIV-1 PROTEASE INHIBITOR CONTAINING A HETEROCYCLIC P1'-P2' AMIDE BOND ISOSTERE
1HPVA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH VX-478, A POTENT AND ORALLY BIOAVAILABLE INHIBITOR OF THE ENZYME
1HPXA:; B:HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR KNI-272
1HSGA:; B:CRYSTAL STRUCTURE AT 1.9 ANGSTROMS RESOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES
1HSHA:; B:; C:; D:CRYSTAL STRUCTURE AT 1.9 ANGSTROMS RESOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES
1HTEA:; B:X-RAY CRYSTALLOGRAPHIC STUDIES OF A SERIES OF PENICILLIN-DERIVED ASYMMETRIC INHIBITORS OF HIV-1 PROTEASE
1HTFA:; B:X-RAY CRYSTALLOGRAPHIC STUDIES OF A SERIES OF PENICILLIN-DERIVED ASYMMETRIC INHIBITORS OF HIV-1 PROTEASE
1HTGA:; B:X-RAY CRYSTALLOGRAPHIC STUDIES OF A SERIES OF PENICILLIN-DERIVED ASYMMETRIC INHIBITORS OF HIV-1 PROTEASE
1HVCA:1B-99B; A:1A-99ACRYSTAL STRUCTURE OF A TETHERED DIMER OF HIV-1 PROTEASE COMPLEXED WITH AN INHIBITOR
1HVHA:; B:NONPEPTIDE CYCLIC CYANOGUANIDINES AS HIV PROTEASE INHIBITORS
1HVIA:; B:INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE
1HVJA:; B:INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE
1HVKA:; B:INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE
1HVLA:; B:INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE
1HVRA:; B:RATIONAL DESIGN OF POTENT, BIOAVAILABLE, NONPEPTIDE CYCLIC UREAS AS HIV PROTEASE INHIBITORS
1HVSA:; B:STRUCTURAL BASIS OF DRUG RESISTANCE FOR THE V82A MUTANT OF HIV-1 PROTEASE: BACKBONE FLEXIBILITY AND SUBSITE REPACKING
1HWRA:; B:MOLECULAR RECOGNITION OF CYCLIC UREA HIV PROTEASE INHIBITORS
1HXBA:; B:HIV-1 PROTEINASE COMPLEXED WITH RO 31-8959
1HXWA:; B:HIV-1 PROTEASE DIMER COMPLEXED WITH A-84538
1IIQA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR
1IZHA:; B:INHIBITOR OF HIV PROTEASE WITH UNUSUAL BINDING MODE POTENTLY INHIBITING MULTI-RESISTANT PROTEASE MUTANTS
1IZIA:; B:INHIBITOR OF HIV PROTEASE WITH UNUSUAL BINDING MODE POTENTLY INHIBITING MULTI-RESISTANT PROTEASE MUTANTS
1K1TA:; B:COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE
1K1UA:; B:COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE
1K2BA:; B:COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE
1K2CA:; B:COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE
1K6CA:; B:LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1K6PA:; B:LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1K6TA:; B:LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1K6VA:; B:LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1KJ4A:; B:; C:; D:SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJ7A:; B:SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJFA:; B:SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJGA:; B:SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJHA:; B:SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KZKA:; B:JE-2147-HIV PROTEASE COMPLEX
1LV1A:1-99; A:1001-1099CRYSTAL STRUCTURE ANALYSIS OF THE NON-ACTIVE SITE MUTANT OF TETHERED HIV-1 PROTEASE TO 2.1A RESOLUTION
1LZQA:; B:CRYSTAL STRUCTURE OF THE COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH AN ETHYLENAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[CH2CH2NH]-PHE-GLU-PHE-NH2
1M0BA:; B:HIV-1 PROTEASE IN COMPLEX WITH AN ETHYLENEAMINE INHIBITOR
1MERA:; B:HIV-1 MUTANT (I84V) PROTEASE COMPLEXED WITH DMP450
1MESA:; B:HIV-1 MUTANT (I84V) PROTEASE COMPLEXED WITH DMP323
1META:; B:HIV-1 MUTANT (V82F) PROTEASE COMPLEXED WITH DMP323
1MEUA:; B:HIV-1 MUTANT (V82F, I84V) PROTEASE COMPLEXED WITH DMP323
1MRWA:; B:STRUCTURE OF HIV PROTEASE (MUTANT Q7K L33I L63I) COMPLEXED WITH KNI-577
1MRXA:; B:STRUCTURE OF HIV PROTEASE (MUTANT Q7K L33I L63I V82F I84V ) COMPLEXED WITH KNI-577
1MSMA:; B:THE HIV PROTEASE (MUTANT Q7K L33I L63I) COMPLEXED WITH KNI-764 (AN INHIBITOR)
1MSNA:; B:THE HIV PROTEASE (MUTANT Q7K L33I L63I V82F I84V) COMPLEXED WITH KNI-764 (AN INHIBITOR)
1MT7A:; B:VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY
1MT8A:; B:VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY
1MT9A:; B:VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY
1MTBA:; B:VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY
1MTRA:; B:HIV-1 PROTEASE COMPLEXED WITH A CYCLIC PHE-ILE-VAL PEPTIDOMIMETIC INHIBITOR
1MUIA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH LOPINAVIR.
1N49A:; B:; C:; D:VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE VARIANT: STRUCTURAL INSIGHTS FOR BETTER ANTI-VIRAL THERAPY
1NH0A:; B:1.03 A STRUCTURE OF HIV-1 PROTEASE: INHIBITOR BINDING INSIDE AND OUTSIDE THE ACTIVE SITE
1NPAA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE-HUP
1NPVA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH LDC271
1NPWA:; B:CRYSTAL STRUCTURE OF HIV PROTEASE COMPLEXED WITH LGZ479
1ODWA:; B:NATIVE HIV-1 PROTEINASE
1ODXA:; B:HIV-1 PROTEINASE MUTANT A71T, V82A
1ODYA:; B:HIV-1 PROTEASE COMPLEXED WITH AN INHIBITOR LP-130
1OHRA:; B:VIRACEPT (R) (NELFINAVIR MESYLATE, AG1343): A POTENT ORALLY BIOAVAILABLE INHIBITOR OF HIV-1 PROTEASE
1PROA:; B:HIV-1 PROTEASE DIMER COMPLEXED WITH A-98881
1Q9PA:SOLUTION STRUCTURE OF THE MATURE HIV-1 PROTEASE MONOMER
1QBRA:; B:HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
1QBSA:; B:HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
1QBTA:; B:HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
1QBUA:; B:HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
1RL8A:; B:CRYSTAL STRUCTURE OF THE COMPLEX OF RESISTANT STRAIN OF HIV-1 PROTEASE(V82A MUTANT) WITH RITONAVIR
1RPIA:; B:CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HIV-1 PROTEASE REVEAL AN EXPANDED ACTIVE SITE CAVITY
1RQ9A:; B:CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HIV-1 PROTEASE REVEAL AN EXPANDED ACTIVE SITE CAVITY
1RV7A:; B:CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HIV-1 PROTEASE REVEAL AN EXPANDED ACTIVE SITE CAVITY
1SBGA:; B:AN ORALLY-BIOAVAILABLE HIV-1 PROTEASE INHIBITOR CONTAINING AN IMIDAZOLE-DERIVED PEPTIDE BOND REPLACEMENT. CRYSTALLOGRAPHIC AND PHARMACOKINETIC ANALYSIS
1SDTA:; B:CRYSTAL STRUCTURES OF HIV PROTEASE V82A AND L90M MUTANTS REVEAL CHANGES IN INDINAVIR BINDING SITE.
1SDUA:; B:CRYSTAL STRUCTURES OF HIV PROTEASE V82A AND L90M MUTANTS REVEAL CHANGES IN INDINAVIR BINDING SITE.
1SDVA:; B:CRYSTAL STRUCTURES OF HIV PROTEASE V82A AND L90M MUTANTS REVEAL CHANGES IN INDINAVIR BINDING SITE.
1SGUA:; B:COMPARING THE ACCUMULATION OF ACTIVE SITE AND NON-ACTIVE SITE MUTATIONS IN THE HIV-1 PROTEASE
1SH9A:; B:COMPARING THE ACCUMULATION OF ACTIVE SITE AND NON-ACTIVE SITE MUTATIONS IN THE HIV-1 PROTEASE
1SP5A:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH A PRODUCT OF AUTOPROTEOLYSIS
1T3RA:; B:HIV PROTEASE WILD-TYPE IN COMPLEX WITH TMC114 INHIBITOR
1T7IA:; B:THE STRUCTURAL AND THERMODYNAMIC BASIS FOR THE BINDING OF TMC114, A NEXT-GENERATION HIV-1 PROTEASE INHIBITOR.
1T7JA:; B:CRYSTAL STRUCTURE OF INHIBITOR AMPRENAVIR IN COMPLEX WITH A MULTI-DRUG RESISTANT VARIANT OF HIV-1 PROTEASE (L63P/V82T/I84V)
1T7KA:; B:CRYSTAL STRUCTURE OF HIV PROTEASE COMPLEXED WITH ARYLSULFONAMIDE AZACYCLIC UREA
1TCXA:; B:HIV TRIPLE MUTANT PROTEASE COMPLEXED WITH INHIBITOR SB203386
1TSQA:1-99; B:1-99CRYSTAL STRUCTURE OF AP2V SUBSTRATE VARIANT OF NC-P1 DECAMER PEPTIDE IN COMPLEX WITH V82A/D25N HIV-1 PROTEASE MUTANT
1TSUA:1-99; B:1-99CRYSTAL STRUCTURE OF DECAMER NCP1 SUBSTRATE PEPTIDE IN COMPLEX WITH WILD-TYPE D25N HIV-1 PROTEASE VARIANT
1TW7A:; B:WIDE OPEN 1.3A STRUCTURE OF A MULTI-DRUG RESISTANT HIV-1 PROTEASE REPRESENTS A NOVEL DRUG TARGET
1U8GA:; B:CRYSTAL STRUCTURE OF A HIV-1 PROTEASE IN COMPLEX WITH PEPTIDOMIMETIC INHIBITOR KI2-PHE-GLU-GLU-NH2
1UPJA:HIV-1 PROTEASE COMPLEX WITH U095438 [3-[1-(4-BROMOPHENYL) ISOBUTYL]-4-HYDROXYCOUMARIN
1VIJA:; B:HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR HOE/BAY 793 HEXAGONAL FORM
1VIKA:; B:HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR HOE/BAY 793 ORTHORHOMBIC FORM
1W5VA:; B:HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1W5WA:; B:HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1W5XA:HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1W5YA:; B:HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1WBKA:; B:HIV-1 PROTEASE IN COMPLEX WITH ASYMMETRIC INHIBITOR, BEA568
1WBMA:; B:HIV-1 PROTEASE IN COMPLEX WITH SYMMETRIC INHIBITOR, BEA450
1XL2A:; B:HIV-1 PROTEASE IN COMPLEX WITH PYRROLIDINMETHANAMINE
1XL5A:; B:HIV-1 PROTEASE IN COMPLEX WITH AMIDHYROXYSULFONE
1YTGA:; B:SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
1YTHA:; B:SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
1Z1HA:1-99; B:101-199HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 3
1Z1RA:1-99; B:101-199HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 2
1ZBGA:; B:CRYSTAL STRUCTURE OF A COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
1ZJ7A:CRYSTAL STRUCTURE OF A COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[S-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
1ZLFA:; B:CRYSTAL STRUCTURE OF A COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR
1ZP8A:HIV PROTEASE WITH INHIBITOR AB-2
1ZPAA:HIV PROTEASE WITH SCRIPPS AB-3 INHIBITOR
1ZPKA:; B:CRYSTAL STRUCTURE OF THE COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
1ZSFA:; B:CRYSTAL STRUCTURE OF COMPLEX OF A HYDROXYETHYLAMINE INHIBITOR WITH HIV-1 PROTEASE AT 2.0A RESOLUTION
1ZSRA:; B:CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE (BRU ISOLATE) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[S-CH(OH) CH2NH]-PHE-GLU-PHE-NH2
1ZTZA:; B:CRYSTAL STRUCTURE OF HIV PROTEASE- METALLACARBORANE COMPLEX
2A1EA:; B:HIGH RESOLUTION STRUCTURE OF HIV-1 PR WITH TS-126
2A4FA:; B:SYNTHESIS AND ACTIVITY OF N-AXYL AZACYCLIC UREA HIV-1 PROTEASE INHIBITORS WITH HIGH POTENCY AGAINST MULTIPLE DRUG RESISTANT VIRAL STRAINS.
2AIDA:; B:STRUCTURE OF A NON-PEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE: DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN
2AOFA:; B:CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A SUBSTRATE ANALOG P1-P6
2AQUA:; B:STRUCTURE OF HIV-1 PROTEASE BOUND TO ATAZANAVIR
2AVMA:; B:KINETICS, STABILITY, AND STRUCTURAL CHANGES IN HIGH RESOLUTION CRYSTAL STRUCTURES OF HIV-1 PROTEASE WITH DRUG RESISTANT MUTATIONS L24I, I50V, AND G73S
2AVOA:; B:KINETICS, STABILITY, AND STRUCTURAL CHANGES IN HIGH RESOLUTION CRYSTAL STRUCTURES OF HIV-1 PROTEASE WITH DRUG RESISTANT MUTATIONS L24I, I50V, AND G73S
2AVSA:; B:KINETICS, STABILITY, AND STRUCTURAL CHANGES IN HIGH RESOLUTION CRYSTAL STRUCTURES OF HIV-1 PROTEASE WITH DRUG RESISTANT MUTATIONS L24I, I50V, AND G73S
2AVVA:; B:; D:; E:KINETICS, STABILITY, AND STRUCTURAL CHANGES IN HIGH RESOLUTION CRYSTAL STRUCTURES OF HIV-1 PROTEASE WITH DRUG RESISTANT MUTATIONS L24I, I50V, AND G73S
2AZ8A:HIV-1 PROTEASE NL4-3 IN COMPLEX WITH INHIBITOR, TL-3
2AZ9A:HIV-1 PROTEASE NL4-3 1X MUTANT
2AZBA:HIV-1 PROTEASE NL4-3 3X MUTANT IN COMPLEX WITH INHIBITOR, TL-3
2AZCA:; B:HIV-1 PROTEASE NL4-3 6X MUTANT
2BB9A:; B:STRUCTURE OF HIV1 PROTEASE AND AKC4P_133A COMPLEX.
2BBBA:; B:STRUCTURE OF HIV1 PROTEASE AND HH1_173_3A COMPLEX.
2BPVA:; B:HIV-1 PROTEASE-INHIBITOR COMPLEX
2BPWA:; B:HIV-1 PROTEASE-INHIBITOR COMPLEX
2BPXA:; B:HIV-1 PROTEASE-INHIBITOR COMPLEX
2BPYA:; B:HIV-1 PROTEASE-INHIBITOR COMPLEX
2BPZA:; B:HIV-1 PROTEASE-INHIBITOR COMPLEX
2BQVA:; B:HIV-1 PROTEASE IN COMPLEX WITH INHIBITOR AHA455
2CEJA:; B:P1' EXTENDED HIV-1 PROTEASE INHIBITORS ENCOMPASSING A TERTIARY ALCOHOL IN THE TRANSITION-STATE MIMICKING SCAFFOLD
2CEMA:; B:P1' EXTENDED HIV-1 PROTEASE INHIBITORS ENCOMPASSING A TERTIARY ALCOHOL IN THE TRANSITION-STATE MIMICKING SCAFFOLD
2CENA:; B:P1' EXTENDED HIV-1 PROTEASE INHIBITORS ENCOMPASSING A TERTIARY ALCOHOL IN THE TRANSITION-STATE MIMICKING SCAFFOLD
2F80A:; B:HIV-1 PROTEASE MUTANT D30N COMPLEXED WITH INHIBITOR TMC114
2F81A:; B:HIV-1 PROTEASE MUTANT L90M COMPLEXED WITH INHIBITOR TMC114
2F8GA:; B:HIV-1 PROTEASE MUTANT I50V COMPLEXED WITH INHIBITOR TMC114
2FDEA:; B:WILD TYPE HIV PROTEASE BOUND WITH GW0385
2FGUA:; B:X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE T80S VARIANT IN COMPLEX WITH THE INHIBITOR SAQUINAVIR USED TO EXPLORE THE ROLE OF INVARIANT THR80 IN HIV-1 PROTEASE STRUCTURE, FUNCTION, AND VIRAL INFECTIVITY.
2FGVA:; B:X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE T80N VARIANT IN COMPLEX WITH THE INHIBITOR SAQUINAVIR USED TO EXPLORE THE ROLE OF INVARIANT THR80 IN HIV-1 PROTEASE STRUCTURE, FUNCTION, AND VIRAL INFECTIVITY.
2FNSA:; B:CRYSTAL STRUCTURE OF WILD-TYPE INACTIVE (D25N) HIV-1 PROTEASE COMPLEXED WITH WILD-TYPE HIV-1 NC-P1 SUBSTRATE.
2FNTA:; B:CRYSTAL STRUCTURE OF A DRUG-RESISTANT (V82A) INACTIVE (D25N) HIV-1 PROTEASE COMPLEXED WITH AP2V VARIANT OF HIV-1 NC-P1 SUBSTRATE.
2FXDA:; B:X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE IRM MUTANT COMPLEXED WITH ATAZANAVIR (BMS-232632)
2FXEA:; B:X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE CRM MUTANT COMPLEXED WITH ATAZANAVIR (BMS-232632)
2HB3A:; B:WILD-TYPE HIV-1 PROTEASE IN COMPLEX WITH POTENT INHIBITOR GRL06579
2HB4A:STRUCTURE OF HIV PROTEASE NL4-3 IN AN UNLIGANDED STATE
2HS1A:; B:ULTRA-HIGH RESOLUTION X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE V32I MUTANT WITH TMC114 (DARUNAVIR) INHIBITOR
2HS2A:; B:CRYSTAL STRUCTURE OF M46L MUTANT OF HIV-1 PROTEASE COMPLEXED WITH TMC114 (DARUNAVIR)
2HVPA:THREE-DIMENSIONAL STRUCTURE OF ASPARTYL PROTEASE FROM HUMAN IMMUNODEFICIENCY VIRUS HIV-1
2I0AA:; B:CRYSTAL STRUCTURE OF KB-19 COMPLEXED WITH WILD TYPE HIV-1 PROTEASE
2I0DA:; B:CRYSTAL STRUCTURE OF AD-81 COMPLEXED WITH WILD TYPE HIV-1 PROTEASE
2I4DA:; B:CRYSTAL STRUCTURE OF WT HIV-1 PROTEASE WITH GS-8373
2I4UA:; B:HIV-1 PROTEASE WITH TMC-126
2I4VA:; B:HIV-1 PROTEASE I84V, L90M WITH TMC126
2I4WA:; B:HIV-1 PROTEASE WT WITH GS-8374
2I4XA:; B:HIV-1 PROTEASE I84V, L90M WITH GS-8374
2IDWA:; B:CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A POTENT NON-PEPTIDE INHIBITOR (UIC-94017)
2IENA:; B:CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE WITH A POTENT NON-PEPTIDE INHIBITOR (UIC-94017)
2IEOA:; B:CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT I84V WITH A POTENT NON-PEPTIDE INHIBITOR (UIC-94017)
2NMYA:; B:CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A INHIBITOR SAQUINAVIR
2NMZA:; B:CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A INHIBITOR SAQUINAVIR
2NNKA:; B:CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT I84V WITH A INHIBITOR SAQUINAVIR
2NNPA:; B:CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT I84V WITH A INHIBITOR SAQUINAVIR
2NPHA:; B:CRYSTAL STRUCTURE OF HIV1 PROTEASE IN SITU PRODUCT COMPLEX
2O4KA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K) IN COMPLEX WITH ATAZANAVIR
2O4LA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, I50V) IN COMPLEX WITH TIPRANAVIR
2O4NA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE (TRM MUTANT) IN COMPLEX WITH TIPRANAVIR
2O4PA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K) IN COMPLEX WITH TIPRANAVIR
2O4SA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K) IN COMPLEX WITH LOPINAVIR
2P3AA:; B:CRYSTAL STRUCTURE OF THE MULTI-DRUG RESISTANT MUTANT SUBTYPE B HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR
2P3BA:; B:CRYSTAL STRUCTURE OF THE SUBTYPE B WILD TYPE HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR
2P3CA:; B:CRYSTAL STRUCTURE OF THE SUBTYPE F WILD TYPE HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR
2PC0A:APO WILD-TYPE HIV PROTEASE IN THE OPEN CONFORMATION
2PK5A:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I ) IN COMPLEX WITH KNI-10075
2PK6A:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10033
2PQZA:; B:HIV-1 PROTEASE IN COMPLEX WITH A PYRROLIDINE-BASED INHIBITOR
2PSUA:; B:CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH CARB-AD37
2PSVA:; B:CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH CARB-KB45
2PWCA:; B:HIV-1 PROTEASE IN COMPLEX WITH A AMINO DECORATED PYRROLIDINE-BASED INHIBITOR
2PWRA:; B:HIV-1 PROTEASE IN COMPLEX WITH A CARBAMOYL DECORATED PYRROLIDINE-BASED INHIBITOR
2PYMA:; B:HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
2PYNA:; B:HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
2Q3KA:; B:CRYSTAL STRUCTURE OF LYSINE SULFONAMIDE INHIBITOR REVEALS THE DISPLACEMENT OF THE CONSERVED FLAP WATER MOLECULE IN HIV-1 PROTEASE
2Q54A:; B:CRYSTAL STRUCTURE OF KB73 BOUND TO HIV-1 PROTEASE
2Q55A:; B:CRYSTAL STRUCTURE OF KK44 BOUND TO HIV-1 PROTEASE
2Q5KA:; B:CRYSTAL STRUCTURE OF LOPINAVIR BOUND TO WILD TYPE HIV-1 PROTEASE
2Q63A:; B:HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
2Q64A:; B:HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
2QCIA:; B:HIV-1 PROTEASE MUTANT D30N WITH POTENT ANTIVIRAL INHIBITOR GRL-98065
2QD7A:; B:HIV-1 PROTEASE MUTANT V82A WITH POTENT ANTIVIRAL INHIBITOR GRL-98065
2QD8A:; B:HIV-1 PROTEASE MUTANT I84V WITH POTENT ANTIVIRAL INHIBITOR GRL-98065
2QHCA:; B:THE INFLUENCE OF I47A MUTATION ON REDUCED SUSCEPTIBILITY TO THE PROTEASE INHIBITOR LOPINAVIR
2QHYA:; B:CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-AC86 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QHZA:; B:CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-AC87 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI0A:; B:CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-KK80 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI1A:; B:CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-KK81 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI3A:; B:CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-AD94 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI4A:; B:CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-AD93 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI5A:; B:CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-KC08 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI6A:; B:CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-KB98 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI7A:; B:CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-AD86 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QNNA:; B:HIV-1 PROTEASE IN COMPLEX WITH A MULTIPLE DECORATED PYRROLIDINE-BASED INHIBITOR
2QNPA:; B:HIV-1 PROTEASE IN COMPLEX WITH A IODO DECORATED PYRROLIDINE-BASED INHIBITOR
2QNQA:; B:HIV-1 PROTEASE IN COMPLEX WITH A CHLORO DECORATED PYRROLIDINE-BASED INHIBITOR
2R38A:; B:I84V HIV-1 PROTEASE MUTANT IN COMPLEX WITH A CARBAMOYL DECORATED PYRROLIDINE-BASED INHIBITOR
2R3TA:; B:I50V HIV-1 PROTEASE MUTANT IN COMPLEX WITH A CARBAMOYL DECORATED PYRROLIDINE-BASED INHIBITOR
2R3WA:; B:I84V HIV-1 PROTEASE IN COMPLEX WITH A AMINO DECORATED PYRROLIDINE-BASED INHIBITOR
2R43A:; B:I50V HIV-1 PROTEASE IN COMPLEX WITH AN AMINO DECORATED PYRROLIDINE-BASED INHIBITOR
2R5PA:; B:; C:; D:CRYSTAL STRUCTURE ANALYSIS OF HIV-1 SUBTYPE C PROTEASE COMPLEXED WITH INDINAVIR
2R5QA:; B:; C:; D:CRYSTAL STRUCTURE ANALYSIS OF HIV-1 SUBTYPE C PROTEASE COMPLEXED WITH NELFINAVIR
2RKFA:; B:HIV-1 PR RESISTANT MUTANT + LPV
2RKGA:; B:HIV-1 PR RESISTANT MUTANT + LPV
2UPJA:; B:HIV-1 PROTEASE COMPLEX WITH U100313 ([3-[[3-[CYCLOPROPYL [4-HYDROXY-2OXO-6-[1-(PHENYLMETHYL)PROPYL]-2H-PYRAN-3-YL] METHYL]PHENYL]AMINO]-3-OXO-PROPYL]CARBAMIC ACID TERT-BUTYL ESTER)
2UXZA:; B:TWO-CARBON-ELONGATED HIV-1 PROTEASE INHIBITORS WITH A TERTIARY-ALCOHOL-CONTAINING TRANSITION-STATE MIMIC
2UY0A:; B:TWO-CARBON-ELONGATED HIV-1 PROTEASE INHIBITORS WITH A TERTIARY-ALCOHOL-CONTAINING TRANSITION-STATE MIMIC
2WHHA:1-99; A:1001-1099HIV-1 PROTEASE TETHERED DIMER Q-PRODUCT COMPLEX ALONG WITH NUCLEOPHILIC WATER MOLECULE
2Z4OA:; B:WILD TYPE HIV-1 PROTEASE WITH POTENT ANTIVIRAL INHIBITOR GRL-98065
2Z54A:; B:THE INFLUENCE OF I47A MUTATION ON REDUCED SUSCEPTIBILITY TO THE PROTEASE INHIBITOR LOPINAVIR
2ZGAA:HIV-1 PROTEASE IN COMPLEX WITH A DIMETHYLALLYL DECORATED PYRROLIDINE BASED INHIBITOR (HEXAGONAL SPACE GROUP)
2ZYEA:; B:STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH POTENT INHIBITOR KNI-272 DETERMINED BY NEUTRON CRYSTALLOGRAPHY
3A2OA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH KNI-1689
3AIDA:; B:A NEW CLASS OF HIV-1 PROTEASE INHIBITOR: THE CRYSTALLOGRAPHIC STRUCTURE, INHIBITION AND CHEMICAL SYNTHESIS OF AN AMINIMIDE PEPTIDE ISOSTERE
3B7VA:; B:HIV-1 PROTEASE COMPLEXED WITH GEM-DIOL-AMINE TETRAHEDRAL INTERMEDIATE NLLTQI
3B80A:; B:HIV-1 PROTEASE MUTANT I54V COMPLEXED WITH GEM-DIOL-AMINE INTERMEDIATE NLLTQI
3BC4A:I84V HIV-1 PROTEASE IN COMPLEX WITH A PYRROLIDINE DIESTER
3BGBA:; B:HIV-1 PROTEASE IN COMPLEX WITH A ISOBUTYL DECORATED OLIGOAMINE
3BGCA:; B:HIV-1 PROTEASE IN COMPLEX WITH A BENZYL DECORATED OLIGOAMINE
3BVAA:; B:CYSTAL STRUCTURE OF HIV-1 ACTIVE SITE MUTANT D25N AND P2-NC ANALOG INHIBITOR
3BVBA:; B:CYSTAL STRUCTURE OF HIV-1 ACTIVE SITE MUTANT D25N AND INHIBITOR DARUNAVIR
3CKTA:; B:HIV-1 PROTEASE IN COMPLEX WITH A DIMETHYLALLYL DECORATED PYRROLIDINE BASED INHIBITOR (ORTHOROMBIC SPACE GROUP)
3CYWA:; B:EFFECT OF FLAP MUTATIONS ON STRUCTURE OF HIV-1 PROTEASE AND INHIBITION BY SAQUINAVIR AND DARUNAVIR
3CYXA:; B:CRYSTAL STRUCTURE OF HIV-1 MUTANT I50V AND INHIBITOR SAQUINAVIRA
3D1XA:; B:CRYSTAL STRUCTURE OF HIV-1 MUTANT I54M AND INHIBITOR SAQUINAVIR
3D1YA:; B:CRYSTAL STRUCTURE OF HIV-1 MUTANT I54V AND INHIBITOR SAQUINA
3D1ZA:; B:CRYSTAL STRUCTURE OF HIV-1 MUTANT I54M AND INHIBITOR DARUNAVIR
3D20A:; B:CRYSTAL STRUCTURE OF HIV-1 MUTANT I54V AND INHIBITOR DARUNAVIA
3DJKA:; B:WILD TYPE HIV-1 PROTEASE WITH POTENT ANTIVIRAL INHIBITOR GRL-0255A
3DK1A:; B:WILD TYPE HIV-1 PROTEASE WITH POTENT ANTIVIRAL INHIBITOR GRL-0105A
3FX5A:; B:STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH POTENT INHIBITOR KNI-272 DETERMINED BY HIGH RESOLUTION X-RAY CRYSTALLOGRAPHY
3GGAA:; B:; C:; D:; G:; H:HIV PROTEASE INHIBITORS WITH PSEUDO-SYMMETRIC CORES
3GGXA:; B:; C:; D:; E:; F:; G:; H:HIV PROTEASE, PSEUDO-SYMMETRIC INHIBITORS
3GI4A:; B:CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, KB60 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
3GI5A:; B:CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, KB62 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
3GI6A:; B:CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, AD78 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
3HVPA:CONSERVED FOLDING IN RETROVIRAL PROTEASES. CRYSTAL STRUCTURE OF A SYNTHETIC HIV-1 PROTEASE
3I7EA:; B:CO-CRYSTAL STRUCTURE OF HIV-1 PROTEASE BOUND TO A MUTANT RESISTANT INHIBITOR UIC-98038
3I8WA:CRYSTAL STRUCTURE OF A METALLACARBORANE INHIBITOR BOUND TO HIV PROTEASE
3K4VA:; B:; C:; D:NEW CRYSTAL FORM OF HIV-1 PROTEASE/SAQUINAVIR STRUCTURE REVEALS CARBAMYLATION OF N-TERMINAL PROLINE
3KDBA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10006
3KDCA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10074
3KDDA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10265
3KF0A:; B:HIV PROTEASE WITH FRAGMENT 4D9 BOUND
3KFNA:; B:HIV PROTEASE (PR) WITH INHIBITOR TL-3 AND FRAGMENT HIT 4D9 BY SOAKING
3KFPA:HIV PROTEASE (PR) WITH INHIBITOR TL-3 BOUND, AND DMSOS IN EXO SITE
3KFRA:; B:HIV PROTEASE (PR) DIMER WITH INHIBITOR TL-3 BOUND AND FRAGMENT 1F1 IN THE OUTSIDE/TOP OF FLAP
3KFSA:; B:HIV PROTEASE (PR) DIMER WITH INHIBITOR TL-3 BOUND AND FRAGMENT 2F4 IN THE OUTSIDE/TOP OF FLAP
3KT2A:1-99; A:1001-1099CRYSTAL STRUCTURE OF N88D MUTANT HIV-1 PROTEASE
3KT5A:1-99; A:1001-1099CRYSTAL STRUCTURE OF N88S MUTANT HIV-1 PROTEASE
3LZSA:; B:CRYSTAL STRUCTURE OF HIV-1 CRF01_AE PROTEASE IN COMPLEX WITH DARUNAVIR
3LZUA:; B:CRYSTAL STRUCTURE OF A NELFINAVIR RESISTANT HIV-1 CRF01_AE PROTEASE VARIANT (N88S) IN COMPLEX WITH THE PROTEASE INHIBITOR DARUNAVIR.
3M9FA:; B:HIV PROTEASE COMPLEXED WITH COMPOUND 10B
3MWSA:; B:CRYSTAL STRUCTURE OF GROUP N HIV-1 PROTEASE
3N3IA:1-99; A:1001-1099CRYSTAL STRUCTURE OF G48V/C95F TETHERED HIV-1 PROTEASE/SAQUINAVIR COMPLEX
3NDTA:; B:; C:; D:HIV-1 PROTEASE SAQUINAVIR:RITONAVIR 1:1 COMPLEX STRUCTURE
3NDUA:; B:; C:; D:HIV-1 PROTEASE SAQUINAVIR:RITONAVIR 1:5 COMPLEX STRUCTURE
3NDWA:; B:HIV-1 PROTEASE SAQUINAVIR:RITONAVIR 1:15 COMPLEX STRUCTURE
3NDXA:; B:HIV-1 PROTEASE SAQUINAVIR:RITONAVIR 1:50 COMPLEX STRUCTURE
3NU3A:; B:WILD TYPE HIV-1 PROTEASE WITH ANTIVIRAL DRUG AMPRENAVIR
3NU4A:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT V32I WITH ANTIVIRAL DRUG AMPRENAVIR
3NU5A:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I50V WITH ANTIVIRAL DRUG AMPRENAVIR
3NU6A:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I54M WITH ANTIVIRAL DRUG AMPRENAVIR
3NU9A:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I84V WITH ANTIVIRAL DRUG AMPRENAVIR
3NUJA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I54V WITH ANTIVIRAL DRUG AMPRENAVIR
3NUOA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT L90M WITH ANTIVIRAL DRUG AMPRENAVIR
3OQ7A:CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE VARIANTS
3OQAA:CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE VARIANTS
3OQDA:CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE VARIANTS
3OU1A:; B:MDR769 HIV-1 PROTEASE COMPLEXED WITH RH/IN HEPTA-PEPTIDE
3OU4A:; B:MDR769 HIV-1 PROTEASE COMPLEXED WITH TF/PR HEPTA-PEPTIDE
3OUAA:; B:MDR769 HIV-1 PROTEASE COMPLEXED WITH P1/P6 HEPTA-PEPTIDE
3OUDA:; B:MDR769 HIV-1 PROTEASE COMPLEXED WITH CA/P2 HEPTA-PEPTIDE
3OXCA:; B:WILD TYPE HIV-1 PROTEASE WITH ANTIVIRAL DRUG SAQUINAVIR
3OY4A:; B:CRYSTAL STRUCTURE OF HIV-1 L76V PROTEASE IN COMPLEX WITH THE PROTEASE INHIBITOR DARUNAVIR.
3PHVA:X-RAY ANALYSIS OF HIV-1 PROTEINASE AT 2.7 ANGSTROMS RESOLUTION CONFIRMS STRUCTURAL HOMOLOGY AMONG RETROVIRAL ENZYMES
3PJ6A:CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE VARIANTS
3PSUA:HIV-1 PROTEASE IN COMPLEX WITH AN ISOBUTYL DECORATED OLIGOAMINE (SYMMETRIC BINDING MODE)
3PWMA:; B:HIV-1 PROTEASE MUTANT L76V WITH DARUNAVIR
3PWRA:; B:HIV-1 PROTEASE MUTANT L76V COMPLEXED WITH SAQUINAVIR
3QAAA:; B:HIV-1 WILD TYPE PROTEASE WITH A SUBSTITUTED BIS-TETRAHYDROFURAN INHIBITOR, GRL-044-10A
3R0WA:; B:CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT HIV-1 PROTEASE IN COMPLEX WITH MECHANISM-BASED ASPARTYL PROTEASE INHIBITORS.
3R0YA:; B:CRYSTAL STRUCTURES OF MULTIDRUG-RESISTANT HIV-1 PROTEASE IN COMPLEX WITH MECHANISM-BASED ASPARTYL PROTEASE INHIBITORS
3S43A:; B:HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH ANTIVIRAL DRUG AMPRENAVIR
3S53A:; B:HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH ANTIVIRAL DRUG DARUNAVIR IN SPACE GROUP P212121
3S54A:; B:HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH ANTIVIRAL DRUG DARUNAVIR IN SPACE GROUP P21212
3S56A:; B:HIV-1 PROTEASE TRIPLE MUTANTS V32I, I47V, V82I WITH ANTIVIRAL DRUG SAQUINAVIR
3S85A:; B:; C:; D:; E:; F:; G:; H:; I:; J:; K:; L:DISCOVERY OF NEW HIV PROTEASE INHIBITORS WITH POTENTIAL FOR CONVENIENT DOSING AND REDUCED SIDE EFFECTS: A-790742 AND A-792611.
3SO9A:; B:DARUNAVIR IN COMPLEX WITH A HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE VARIANT
3SPKA:; B:TIPRANAVIR IN COMPLEX WITH A HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE VARIANT
3ST5A:; B:CRYSTAL STRUCTURE OF WILD-TYPE HIV-1 PROTEASE WITH C3-SUBSTITUTED HEXAHYDROCYCLOPENTAFURANYL URETHANE AS P2-LIGAND, GRL-0489A
3T11A:; B:DIMERIC INHIBITOR OF HIV-1 PROTEASE.
3T3CA:; B:STRUCTURE OF HIV PR RESISTANT PATIENT DERIVED MUTANT (COMPRISING 22 MUTATIONS) IN COMPLEX WITH DRV
3TKGA:; B:; C:; D:CRYSTAL STRUCTURE OF HIV MODEL PROTEASE PRECURSOR/SAQUINAVIR COMPLEX
3TKWA:; B:CRYSTAL STRUCTURE OF HIV PROTEASE MODEL PRECURSOR/DARUNAVIR COMPLEX
3TL9A:; B:CRYSTAL STRUCTURE OF HIV PROTEASE MODEL PRECURSOR/SAQUINAVIR COMPLEX
3TLHA:STRUCTURAL STUDIES OF HIV AND FIV PROTEASES COMPLEXED WITHAN EFFICIENT INHIBITOR OF FIV PR
3U71A:CRYSTAL STRUCTURE ANALYSIS OF SOUTH AFRICAN WILD TYPE HIV-1 SUBTYPE C PROTEASE
3U7SA:; B:HIV PR DRUG RESISTANT PATIENT'S VARIANT IN COMPLEX WITH DARUNAVIR
3UCBA:; B:CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20 IN COMPLEX WITH DARUNAVIR
3UF3A:; B:CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20
3UFNA:; B:CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20 IN COMPLEX WITH SAQUINAVIR
3UHLA:; B:; C:; D:CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20 IN COMPLEX WITH P2-NC SUBSTRATE ANALOG
4DFGA:; B:CRYSTAL STRUCTURE OF WILD-TYPE HIV-1 PROTEASE WITH CYCLOPENTYLTETRAHYDRO- FURANYL URETHANES AS P2-LIGAND, GRL-0249A
4DQBA:; B:CRYSTAL STRUCTURE OF WILD-TYPE HIV-1 PROTEASE IN COMPLEX WITH DRV
4DQCA:; B:CRYSTAL STRUCTURE OF (G16C/L38C) HIV-1 PROTEASE IN COMPLEX WITH DRV
4DQEA:; B:CRYSTAL STRUCTURE OF (G16C/L38C) HIV-1 PROTEASE IN COMPLEX WITH DRV
4DQFA:; B:CRYSTAL STRUCTURE OF (G16A/L38A) HIV-1 PROTEASE IN COMPLEX WITH DRV
4DQGA:; B:CRYSTAL STRUCTURE OF APO(G16C/L38C) HIV-1 PROTEASE
4DQHA:; B:CRYSTAL STRUCTURE OF (R14C/E65C) HIV-1 PROTEASE IN COMPLEX WITH DRV
4E43A:; B:HIV PROTEASE (PR) DIMER WITH ACETATE IN EXO SITE AND PEPTIDE IN ACTIVE SITE
4EJKA:; B:HIV PROTEASE (PR) DIMER IN CLOSED FORM WITH PEPSTATIN IN ACTIVE SITE AND FRAGMENT 1F1-N IN THE OUTSIDE/TOP OF FLAP
4EYRA:; B:CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE IN COMPLEX WITH RITONAVIR
4FAFA:; B:SUBSTRATE CA/P2 IN COMPLEX WITH A HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE VARIANT
4FE6A:CRYSTAL STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH AN ENAMINO-OXINDOLE INHIBITOR
4FM6A:; B:HIV-1 PROTEASE MUTANT V32I COMPLEXED WITH REACTION INTERMEDIATE
4GZFA:; B:MULTI-DRUG RESISTANT HIV-1 PROTEASE 769 VARIANT WITH REDUCED LRF PEPTIDE
4HDBA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANTS D30N COMPLEXED WITH INHIBITOR GRL-0519
4HDFA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANTS V82A COMPLEXED WITH INHIBITOR GRL-0519
4HDPA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANTS I50V COMPLEXED WITH INHIBITOR GRL-0519
4HE9A:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANTS I54M COMPLEXED WITH INHIBITOR GRL-0519
4HEGA:; B:CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANTS R8Q COMPLEXED WITH INHIBITOR GRL-0519
4HVPA:; B:STRUCTURE OF COMPLEX OF SYNTHETIC HIV-1 PROTEASE WITH A SUBSTRATE-BASED INHIBITOR AT 2.3 ANGSTROMS RESOLUTION
4I8WA:; B:CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH NON-PEPTIDIC INHIBITOR, GRL007
4I8ZA:; B:CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH NON-PEPTIDIC INHIBITOR, GRL008
4J54A:; B:CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20 WITH THE POTENT ANTIVIRAL INHIBITOR GRL-0519A
4J55A:; B:CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20 WITH THE POTENT ANTIVIRAL INHIBITOR GRL-02031
4J5JA:; B:CRYSTAL STRUCTURE OF MULTIDRUG RESISTANT HIV-1 PROTEASE CLINICAL ISOLATE PR20 IN COMPLEX WITH AMPRENAVIR
4JECA:; B:JOINT NEUTRON AND X-RAY STRUCTURE OF PER-DEUTERATED HIV-1 PROTEASE IN COMPLEX WITH CLINICAL INHIBITOR AMPRENAVIR
4K4PA:; B:TL-3 INHIBITED TRP6ALA HIV PROTEASE
4K4RA:; B:TL-3 INHIBITED TRP6ALA HIV PROTEASE WITH 1-BROMO-2-NAPTHOIC ACID BOUND IN EXOSITE
4KB9A:; B:CRYSTAL STRUCTURE OF WILD-TYPE HIV-1 PROTEASE WITH NOVEL TRICYCLIC P2-LIGANDS GRL-0739A
4L1AA:; B:CRYSTALLOGRAPHIC STUDY OF MULTI-DRUG RESISTANT HIV-1 PROTEASE LOPINAVIR COMPLEX: MECHANISM OF DRUG RECOGNITION AND RESISTANCE
4MC1A:; B:HIV PROTEASE IN COMPLEX WITH SA526P
4MC2A:; B:HIV PROTEASE IN COMPLEX WITH SA525P
4MC6A:; B:HIV PROTEASE IN COMPLEX WITH SA499
4MC9A:; B:HIV PROTEASE IN COMPLEX WITH AA74
4PHVA:; B:X-RAY CRYSTAL STRUCTURE OF THE HIV PROTEASE COMPLEX WITH L-700,417, AN INHIBITOR WITH PSEUDO C2 SYMMETRY
5HVPA:; B:CRYSTALLOGRAPHIC ANALYSIS OF A COMPLEX BETWEEN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AND ACETYL-PEPSTATIN AT 2.0-ANGSTROMS RESOLUTION
7HVPA:; B:X-RAY CRYSTALLOGRAPHIC STRUCTURE OF A COMPLEX BETWEEN A SYNTHETIC PROTEASE OF HUMAN IMMUNODEFICIENCY VIRUS 1 AND A SUBSTRATE-BASED HYDROXYETHYLAMINE INHIBITOR
8HVPA:; B:STRUCTURE AT 2.5-ANGSTROMS RESOLUTION OF CHEMICALLY SYNTHESIZED HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE COMPLEXED WITH A HYDROXYETHYLENE*-BASED INHIBITOR
9HVPA:; B:DESIGN, ACTIVITY AND 2.8 ANGSTROMS CRYSTAL STRUCTURE OF A C2 SYMMETRIC INHIBITOR COMPLEXED TO HIV-1 PROTEASE